ViiV Healthcare
Clinical trials sponsored by ViiV Healthcare, explained in plain language.
Now part of
GSK
GSK
NYSE
A global specialist HIV company, majority-owned by GSK.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New HIV antibody VH4527079 enters early human safety testing Results expected Sep 2026 (estimated)
- New HIV prevention shot could last 4 months Results expected Sep 2026 (estimated)
- Can a new drug combo flush out hidden HIV? Results expected Jan 2027 (estimated)
- New HIV pill VH4770359 enters first human safety tests Results expected May 2027 (estimated)
- New HIV prevention shot gets a boost: enzyme may make injections last longer Results expected Jun 2027 (estimated)